South Korean pharmaceutical company Hanmi Pharm recently entered into an exclusive distribution agreement with Mexico's Laboratorios Sanfer. The collaboration covers the diabetes franchise products, including efinopegdutide and dapagliflozin. According to the agreement, Sanfer will be responsible for the regulatory approval, marketing, distribution, and sales of the related products in Mexico.

Under this partnership, Hanmi Pharm will supply its long-acting GLP-1 obesity candidate drug, efinopegdutide, along with two products: Dapagliflozin Tab and Dapagliflozin Dual SR Tab. This move signifies Hanmi Pharm's further advancement of efinopegdutide in the international market after regaining global rights several years ago. Through the collaboration with Sanfer, Hanmi Pharm aims to expand the influence of its diabetes and obesity treatment drugs in the important Mexican market.

Ricardo Amtmann, CEO of Sanfer, stated: "This collaboration aims to address the growing demand for obesity and diabetes treatments in Mexico. Currently, local medical expenses impose a heavy burden on many families. We hope that by providing high-quality treatment drugs, we can help patients alleviate financial pressure and improve their quality of life."